Introduction
============

Assessment of kidney function is important in clinical practice for determining overall health, selecting correct dosages for drugs cleared by the kidneys, preparing for therapeutic procedures and detecting acute and chronic kidney disease (CKD). Assessment of kidney function is also important because impaired kidney function is strongly associated with cardiac diseases \[[@bib1]--[@bib3]\]. Epidemiologic studies have shown that CKD in many countries has a prevalence of \>10% \[[@bib4]\] and that prevalence is rising \[[@bib5]\]. However, the best index of kidney function, glomerular filtration rate (GFR), cannot be measured easily in clinical practice. Indirect estimation of GFR from serum creatinine has long been the only method practical for routine clinical testing, but serum creatinine has several limitations. Therefore, the recommended method for evaluating kidney function is to use the serum creatinine value in a formula that estimates GFR.

Cystatin C has many characteristics of an ideal endogenous GFR marker \[[@bib6]\]. Several investigations have indicated that serum cystatin C is as good as or better than serum creatinine as a GFR marker in patients with native kidneys, especially in patients with mild or moderate reduction of GFR \[[@bib7]--[@bib10]\]. In a meta-analysis, serum cystatin C was superior to creatinine in measuring renal function both in children and adults \[[@bib7]\]. However, there are conflicting results, and some investigators have not found cystatin C to be advantageous \[[@bib11]\]. One possible reason for conflicting results on the relationship between GFR and cystatin C is that factors other than GFR may affect serum cystatin C levels \[[@bib11]--[@bib13]\]. Another possible reason is that some of the studies used samples that had been stored for a long period of time, which may have caused analytical problems. Nevertheless, the promising results on estimating renal function from cystatin C have led to the development of commercial assays, sold as reagent kits, which use polyclonal antibodies against cystatin C. Signal detection is based on light scattering in particle-enhanced turbidimetric and nephelometric immunoassays (PETIA and PENIA, respectively). However, the use of polyclonal antibodies can cause variation from batch to batch. In addition, the use of light scattering can render the assay susceptible to interfering factors such as lipemia, hemolysis and bilirubinemia. This interference is recognized on turbidimetric detection principles. Samples that have been stored may have other drawbacks in turbidimetric assays, such as opalescence from precipitated lipids.

A newly designed assay for cystatin C based on two monoclonal antibodies and time-resolved fluorescent detection \[[@bib14]\] is potentially less prone to these forms of interference. The use of monoclonal instead of polyclonal antibodies makes the assay more uniform and stable. The monoclonal antibody combination in the new assay gives fast binding and good correlation (*R* = 0.949) with a PETIA assay from Roche (Basel, Switzerland). The new assay also demonstrates excellent linearity and a wide linear range in measuring cystatin C concentrations, covering all clinically relevant concentrations of cystatin C, and the assay measures highly similar concentrations of cystatin C in serum samples compared to anticoagulated plasma samples \[[@bib14]\]. The imprecision of the new assay is also suggested to be low with a total imprecision of \<5.6% \[[@bib14]\]. The new assay for cystatin C is sensitive and therefore uses extensive sample dilution, which diminishes possible interference from the sample, particularly interference caused by heterophilic antibodies. In addition, a wash step prior to detection in the new assay removes blood components that could potentially interfere with signal detection.

The aim of this study was to evaluate the performance of the new assay in patients with normal and reduced kidney function. Results of new and established cystatin C assays and creatinine assays were compared to plasma clearance of iohexol, which we considered the gold standard for assessment of GFR.

Materials and methods
=====================

Patients and blood collection
-----------------------------

Two groups of patients were used in these analyses: those with normal renal function (Group A) and those with slight to advanced renal dysfunction (Group B). Group A consisted of 220 consecutive male patients without known renal disease seen at the Department of Urology, Skåne University Hospital, Sweden, during October 2001 and April 2004. Those missing data for iohexol clearance (*n* = 7), cystatin C (*n* = 9) or creatinine (*n* = 34) were excluded, leaving 170 patients in Group A available for analysis. In this group, we collected three blood samples for analysis of variability. The median interval between Time 1 (before measurement of iohexol clearance) and Time 2 (immediately after iohexol clearance) was 4 h (range: 3--7 h); the median interval between Time 1 and Time 3 was 12 days (range: 6--38 days). The samples from Times 2 and 3 were used only in the variability analysis.

Group B consisted of 108 patients with CKD enrolled at the Department of Nephrology and Transplantation, Skåne University Hospital, Sweden. During 2004 and 2006, at routine visits for GFR determination with iohexol clearance, consecutive men were invited to participate in the study, and all accepted the invitation. Those missing data for iohexol clearance (*n* = 1) or cystatin C (*n* = 3) were excluded, leaving 104 patients in Group B available for analysis. The included men had been diagnosed with diabetic nephropathy (*n* = 21), glomerulonephritis (*n* = 22), non-specified renal disease (*n* = 14), nephrosclerosis (*n* = 15), or a group of miscellaneous renal diseases (*n* = 10), or had renal transplants with stable but reduced renal function (*n* = 22).

Blood was collected by venipuncture, centrifuged within \<1 h at 3500 g for 10 min and then immediately stored at −80°C pending analysis.

Laboratory methods
------------------

### Creatinine.

Plasma creatinine was determined by a creatininase-based procedure using the Hitachi Modular P analysis system (application 652; Roche). The total analytical (intra-assay + inter-assay) imprecision was 3.0% for a control sample at a concentration of 60 μmol/L and 1.4% for a control sample at 578 μmol/L. Reference range for men: 60--100 μmol/L.

### Cystatin C, conventional assay.

Plasma cystatin C was measured by a fully automated PETIA \[[@bib15]\]. The reagents were obtained from DAKO (Dako A/S, Glostrup, Denmark) and the determination was performed on the Hitachi Modular P analysis system. The total analytical imprecision was 2.1% for a control sample at a concentration of 1.0 mg/L and 1.7% for a control sample at 4.0 mg/L. Reference range: 0.55--1.15 mg/L for age 1--50 years and 0.63--1.44 mg/L for age \>50 years \[[@bib16]\].

### Cystatin C, new assay.

Cystatin C concentration of plasma samples was measured with an investigational immunoassay that uses monoclonal antibodies (HyTest, Turku, Finland) for both capture and detection and is based on time-resolved fluorometry \[[@bib14]\]. The assay has a wash step prior to fluorescence measurement and it is performed in all-in-one dry reagent wells, which contain all required assay components, on an automated Aio! Immunoanalyzer (Innotrac Diagnostics, Turku, Finland). One hundred-fold dilution of plasma samples is used and the assay range covers undiluted cystatin C concentrations from 0.1 to 20 mg/L. The bias compared to the conventional assay was 20% on average. The intra-assay imprecision percentages for the new method were 4.6 and 2.8, the inter-assay imprecision percentages 1.9 and 3.2 and the total assay imprecision percentages 4.6 and 5.5 at 0.8 mg/L and 3.2 mg/L, respectively \[[@bib14]\].

### Measured GFR (iohexol clearance).

GFR was determined by measuring the plasma clearance of iohexol according to a one-compartment model, where samples were taken after the distribution phase, in the assumed monoexponential part of the plasma decay curve. Iohexol was analyzed by high-performance liquid chromatography technique \[[@bib17], [@bib18]\].

Statistical methods
-------------------

To facilitate comparisons between cystatin C, creatinine and iohexol measurements, we used 1/cystatin C (L/10^−1^ g) and 1/creatinine (L/10^−2^ mol). These conversions were used for all analyses and in all figures. Iohexol clearance (mL/min/1.73 m^2^) was considered the true GFR (gold standard). To quantify the amount by which values of 1/cystatin C and 1/creatinine differed from GFR, we calculated the concordance correlation coefficient and the 95% limits of agreement. The concordance correlation coefficient combines measures of both precision and accuracy to determine how far the observed data deviate from the line of perfect concordance (i.e. the line at 45° on a square scatter plot). The 95% limits of agreement represent the region within which 95% of the differences between measurements are expected to lie. For illustrative purposes, we created scatter plots of all patients' reciprocal cystatin C or creatinine and GFR measurements. To describe the variability of cystatin C across the three time points, we calculated the intraindividual coefficients of variation. These coefficients of variation were calculated as the ratio of the standard deviation to the mean within each individual and are expressed as percentages. All analyses were conducted separately by cohort because Group A and B represent distinct patient populations. All statistical analyses were conducted using Stata 10.0 (StataCorp, College Station, TX).

Ethical considerations
----------------------

The study was approved by the regional ethics committee at Lund University, Sweden, LU 587-00, and all subjects provided written consent to participate in the study and to allow retrieval of information from medical records.

Results
=======

Patient characteristics and renal function measurements for the two groups are shown in [Table 1](#tbl1){ref-type="table"}. Median age was 65 years in Group A (patients without known CKD) and 57 years Group B (patients with CKD). Overall, cystatin C measurements were lower and more homogenous in Group A than in Group B. Iohexol clearance measurement showed a median GFR of 81 \[range of 29--119, interquartile range (IQR) 70--92\] mL/min/1.73 m^2^ in Group A. This 'normal renal function' group included 49 participants (29%) with no CKD or Stage 1 CKD, 104 (61%) with Stage 2, 16 (9%) with Stage 3 and 1 (0.6%) with Stage 4. In Group B, median GFR measured from iohexol clearance was significantly lower at 23 (range 8--83, IQR 16--34) mL/min/1.73 m^2^. In this group, four patients (4%) had Stage 2 CKD, 29 (28%) had Stage 3 CKD, 51 (49%) had Stage 4 and 20 (19%) had Stage 5.

###### 

Summary of patient characteristics[a](#tblfn1){ref-type="table-fn"}

                                         Group A (normal renal function), *N* = 170   Group B (CKD), *N* = 104
  -------------------------------------- -------------------------------------------- --------------------------
  Age (years)                            65 (60, 71)                                  57 (47, 70)
  Creatinine (μmol/L)                    78 (70, 85)                                  224 (160, 295)
  Conventional cystatin C (mg/L)         1.08 (1.01, 1.16)                            2.63 (2.11, 3.40)
  New cystatin C (mg/L)                  1.03 (0.910, 1.14)                           2.42 (1.91, 3.02)
  Iohexol clearance (mL/min/1.73 m^2^)   81 (70, 92)                                  23 (16, 34)

All values are median (IQR).

[Table 2](#tbl2){ref-type="table"} summarizes the concordance correlation coefficients and limits of agreement for 1/cystatin C and 1/creatinine compared to iohexol clearance. Overall, the agreement between cystatin C and the true GFR was higher in patients with renal disease (Group B) than in those with normal renal function (Group A). When the two cystatin C assays were compared with iohexol clearance in Group A, the conventional assay had a slightly higher concordance correlation than the new assay, whereas in Group B, the new assay had the higher concordance correlation. Both cystatin C assays tended to overestimate true GFR in both cohorts ([Figures 1](#fig1){ref-type="fig"} and [2](#fig2){ref-type="fig"}, [Table 2](#tbl2){ref-type="table"}), but both cystatin C assays exhibited better agreement with iohexol clearance than did creatinine in Group A and B ([Figures 1--3](#fig1 fig2 fig3){ref-type="fig"}). The lowest concordance correlation was shown between 1/creatinine and iohexol clearance. However, at low levels of renal function (GFR \< 30), creatinine appeared to have better agreement with GFR ([Figure 3](#fig3){ref-type="fig"}).

###### 

Agreement of reciprocal creatinine and cystatin C values with measured GFR[a](#tblfn2){ref-type="table-fn"}

                                                 Group A (normal renal function)   Group B (renal disease)                                              
  ---------------------------------------------- --------------------------------- ------------------------- -------------------- ------------- ------- ------------------
  1/Creatinine (L/10^−2^ mol)                    128 (118, 143)                    0.161                     49.9 (16.5, 83.2)    45 (34, 63)   0.499   21.2 (0.1, 42.2)
  1/Conventional cystatin C assay (L/10^−1^ g)   93 (86, 99)                       0.465                     11.6 (−12.6, 35.8)   41 (33, 52)   0.593   16.8 (4.4, 29.3)
  1/New cystatin C assay (L/10^−1^ g)            97 (88, 110)                      0.441                     17.1 (−10.8, 45.1)   38 (29, 48)   0.680   13.1 (0.9, 25.3)

Average difference is the eGFR---true GFR (iohexol clearance).

![Calibration plot of 1/cystatin C values from the conventional assay as compared to iohexol clearance (gold standard). The black line represents perfect agreement. Patients with CKD (Group B) are represented by solid circles; patients without diagnosis of kidney disease (Group A) are represented by hollow circles.](ndtjgfr350f01_lw){#fig1}

![Calibration plot of 1/cystatin C values from the new assay as compared to iohexol clearance (gold standard). The black line represents perfect agreement. Patients with CKD (Group B) are represented by solid circles; patients without diagnosis of kidney disease (Group A) are represented by hollow circles.](ndtjgfr350f02_lw){#fig2}

![Calibration plot of 1/creatinine as compared to iohexol clearance (gold standard). The black line represents perfect agreement. Patients with CKD (Group B) are represented by solid circles; patients without diagnosis of kidney disease (Group A) are represented by hollow circles.](ndtjgfr350f03_lw){#fig3}

[Figure 4](#fig4){ref-type="fig"} shows the correlation plots for reciprocal plasma cystatin C values determined with the conventional and new cystatin C assays. The agreement between the two assays for cystatin C was high, with concordance correlation 0.815 in Group A and 0.935 in Group B. The new assay, compared to the conventional assay, tended to yield slightly higher values at the high end of 1/cystatin C ([Figure 4](#fig4){ref-type="fig"}). The increasing difference between the two methods for cystatin C at higher GFR is also seen in Bland Altman plots for Groups A and B ([Figure 5a and b](#fig5){ref-type="fig"}, respectively).

![Calibration plot of conventional cystatin C assay as compared to the new cystatin C assay. The black line at 45° represents perfect agreement. Patients with CKD (Group B) are represented by solid circles; patients without diagnosis of kidney disease (Group A) are represented by hollow circles.](ndtjgfr350f04_lw){#fig4}

![Bland Altman plots for the two measures of cystatin C, (**a**) for Group A and (**b**) for Group B. The *x*-axis is the average of the two 1/cystatin C measures and the *y*-axis is the difference (conventional method---new method). The horizontal lines represent the average difference and the 95% limits of agreement.](ndtjgfr350f05_lw){#fig5}

We summarized the variation of reciprocal cystatin C levels across different time points as the coefficient of variation measured with the new assay using serial blood samples obtained at three separate time points from the men in Group A ([Table 3](#tbl3){ref-type="table"}). The intraindividual coefficients of variation between the time points were low and relatively consistent. The mean (SD) variation in cystatin C as well as in reciprocal cystatin C was 6% (4%) between Time 1 and 3 and was 5% (4%) both between Time 1 and Time 2 and between Time 2 and Time 3.

###### 

Variation of cystatin C levels between three time points[a](#tblfn3){ref-type="table-fn"}

  Time points      Mean intraindividual coefficient of variation, % (SD)
  ---------------- -------------------------------------------------------
  Time 1, Time 2   5 (4)
  Time 1, Time 3   6 (4)
  Time 2, Time 3   5 (4)

All values were measured with the new assay in Group A.

Discussion
==========

Many studies have shown advantages of cystatin C over creatinine as a GFR marker. Although some studies have not shown such an advantage, almost none have shown better diagnostic performance for creatinine than for cystatin C. However, the established cystatin C assays have some methodologic weaknesses, such as susceptibility to interference from substances in blood, especially in samples that have been stored. Some of these methodologic weaknesses of the standard cystatin C assays are addressed by a recently developed highly sensitive assay for plasma cystatin C that uses two monoclonal antibodies \[[@bib14]\], and the current report is the first clinical evaluation of this new assay. Here, we demonstrate that this new assay performs well compared to the conventional PETIA. In particular, we have demonstrated that the new assay performs better than the old assay in male patients with CKD. Cystatin C, with both assays, is superior to creatinine in correlation with iohexol clearance.

From our findings, that reciprocal cystatin C levels exhibited much better agreement with true GFR than reciprocal creatinine levels, we anticipate that subsequent development and use of an estimated glomerular filtration rate (eGFR) formula that is based on cystatin C, or possibly could incorporate both creatinine and cystatin C, would substantially improve the agreement with measured GFR. However, we did not use the published cystatin C-based eGFR formula, which was developed for use with the conventional assay \[[@bib19]\], as the accuracy of the cystatin C-based eGFR formula would be biased in favor of the conventional assay and would not permit a fair comparison with the new cystatin C assay.

The concordance correlation coefficient with measured GFR was higher in the group of men with impaired renal function for all assessments, both cystatin C assays and creatinine. The reason for this is not completely clear, but formulas for eGFR also perform better in decreased GFR ranges than in the normal range \[[@bib20]\]. It is well known that eGFR calculated by the modification of diet in renal disease formula underestimates GFR in the normal range by up to 30% but only by 6% in patients with CKD.

With the new cystatin C assay, intraindividual variability between time points, described as coefficients of variation, was found to be small and clinically insignificant. This low short-term variability reflects not only the stability of the new assay as a diagnostic test and strengthens the precision, reliability and clinical utility of cystatin C as a GFR marker but also suggests strongly that the intraindividual variation in cystatin C levels in blood among subjects with normal or only moderately impaired GFR is very small. Although the analytical imprecision of the new method is higher than that of the conventional method, the measured intraindividual variation, which sets the actual variability of the test results, was higher than the imprecision of the new cystatin C method.

In this study, the established cystatin C assay used for comparison was a PETIA. A recent investigation has suggested that PENIA may be more reliable than PETIA \[[@bib21]\], which could limit the conclusion of our study. However, numerous studies with PETIA have shown a good correlation with GFR measured by standard methods \[[@bib7], [@bib22]\], and we also had true GFR values included in this study. Nevertheless, our results need to be confirmed in relation to a PENIA. Another possible limitation in comparative studies is that the conventional assays for cystatin C are not standardized. The lack of an international calibrator complicates the estimation of agreement of cystatin C values with true GFR since systematic differences in cystatin C levels between different assay technologies are known to exist and were seen in this study, especially at high levels of cystatin C. The difference between the conventional and the new method is interesting, and it actually seems that compared to the iohexol GFR values, 1/cystatin C measured with the new assay shows a higher parallelism to the line of identity than does 1/cystatin C measured with the conventional assay. The nonlinear association between the cystatin C assays could be related to the fact that the linear range of the conventional method is narrower compared to other commercial cystatin C methods.

A strength of our study is the wide range of GFR encompassed by the study groups with and without known CKD. It is both a strength and limitation in our study that we assessed male patients only. The advantage of examining renal function according to sex is that we do not have to account for known differences in creatinine between males and females. However, as a limitation, these results need to be confirmed in a female population, which is a future project of ours. If similar data showing high concordance correlation between the new cystatin C assay and iohexol clearance can be replicated also in women, it would be appropriate to develop a formula for eGFR based on this new cystatin C assay. The ongoing development of an international calibrator will further strengthen cystatin C as a GFR marker.

Conclusion
==========

In this first clinical evaluation, the new assay for cystatin C shows good agreement with the established conventional PETIA. In patients with CKD, it showed better agreement with true GFR than PETIA. These results imply that the new assay may be an alternative to the present commercial assays.
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